184 related articles for article (PubMed ID: 24490654)
1. Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.
Duflot T; Roche C; Lamoureux F; Guerrot D; Bellien J
Expert Opin Drug Discov; 2014 Mar; 9(3):229-43. PubMed ID: 24490654
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?
Bellien J; Joannides R; Richard V; Thuillez C
Pharmacol Ther; 2011 Jul; 131(1):1-17. PubMed ID: 21514320
[TBL] [Abstract][Full Text] [Related]
3. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
5. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
[TBL] [Abstract][Full Text] [Related]
6. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
Ni GH; Chen JF; Chen XP; Yang TL
Pharmazie; 2011 Mar; 66(3):153-7. PubMed ID: 21553642
[TBL] [Abstract][Full Text] [Related]
7. Diabetic CVD--soluble epoxide hydrolase as a target.
Lorthioir A; Guerrot D; Joannides R; Bellien J
Cardiovasc Hematol Agents Med Chem; 2012 Sep; 10(3):212-22. PubMed ID: 22632263
[TBL] [Abstract][Full Text] [Related]
8. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
9. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
10. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
Huang H; Weng J; Wang MH
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
[TBL] [Abstract][Full Text] [Related]
11. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.
Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X
Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225
[TBL] [Abstract][Full Text] [Related]
12. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.
Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M
Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314
[TBL] [Abstract][Full Text] [Related]
13. Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.
Pillarisetti S; Khanna I
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):143-58. PubMed ID: 22280237
[TBL] [Abstract][Full Text] [Related]
14. Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy.
Romashko M; Schragenheim J; Abraham NG; McClung JA
Trends Pharmacol Sci; 2016 Nov; 37(11):945-962. PubMed ID: 27633970
[TBL] [Abstract][Full Text] [Related]
15. Soluble epoxide hydrolase: A potential target for metabolic diseases.
He J; Wang C; Zhu Y; Ai D
J Diabetes; 2016 May; 8(3):305-13. PubMed ID: 26621325
[TBL] [Abstract][Full Text] [Related]
16. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases.
Zordoky BN; El-Kadi AO
Pharmacol Ther; 2010 Mar; 125(3):446-63. PubMed ID: 20093140
[TBL] [Abstract][Full Text] [Related]
17. Targeting epoxides for organ damage in hypertension.
Imig JD
J Cardiovasc Pharmacol; 2010 Oct; 56(4):329-35. PubMed ID: 20531214
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis.
Gurung AB; Mayengbam B; Bhattacharjee A
Comput Biol Chem; 2018 Jun; 74():1-11. PubMed ID: 29522918
[TBL] [Abstract][Full Text] [Related]
19. Soluble epoxide hydrolase inhibitors and heart failure.
Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N
Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684
[TBL] [Abstract][Full Text] [Related]
20. [Soluble epoxide hydrolase and lipid metabolism].
Ma XX; Liu Y; Zhu Y
Sheng Li Ke Xue Jin Zhan; 2010 Aug; 41(4):267-71. PubMed ID: 21416942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
